Optical fiber dosimeter for real-time in-vivo dose monitoring during LDR brachytherapy by Woulfe, Peter et al.
Research Article Vol. 11, No. 7 / 1 July 2020 / Biomedical Optics Express 4027
Optical fiber dosimeter for real-time in-vivo dose
monitoring during LDR brachytherapy
P. WOULFE,1,2,* F. J. SULLIVAN,3,4 W. KAM,1 AND S. O’KEEFFE1
1Optical Fiber Sensors Research Centre, University of Limerick, Ireland
2Dept. of Radiotherapy Physics, Galway Clinic, Ireland
3Prostate Cancer Institute, National University of Ireland Galway, Ireland
4Department of Radiotherapy, Galway Clinic, Ireland
*peter.woulfe@galwayclinic.com
Abstract: An optical fiber sensor for monitoring low dose radiation is presented. The sensor,
based on radiation sensitive scintillation material, terbium doped gadolinium oxysulphide
(Gd2O2S:Tb), is embedded in a cavity of 700µm diameter within a 1mm plastic optical fiber.
The sensor is compared with the treatment planning system for repeatability, angular dependency,
distance and accumulated radiation activity. The sensor demonstrates a high sensitivity of
152 photon counts/Gy with a temporal resolution of 0.1 seconds, with the largest repeatability
error of 4.1%, to 0.361mCi of Iodine-125 the radioactive source most commonly used in LDR
brachytherapy for treating prostate cancer.
© 2020 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
1. Introduction
Prostate brachytherapy (BT) refers to the implantation of radioactive sources (or “seeds”) into the
prostate under image guidance. Low Dose Rate (LDR) brachytherapy is more commonly used in
the treatment of prostate cancer and therefore further discussion of brachytherapy within this
article is limited to this modality. Prostate brachytherapy is typically performed in the course of
2 hours under spinal or general anaesthesia in an outpatient setting. Many patients tend to be in
favour of this option as it typically takes only a few hours with little post-operative recovery [1].
Prior to the procedure, the patient undergoes a transrectal ultrasound or Computed Tomography
(CT)/ Magnetic Resonance Imaging (MRI) based volume study. This information then allows
the radiation oncologist to pre-plan the 3D seed distribution required to deliver the prescribed
dose to the prostate. Seventy five percent of the Iodine-125 seeds are inserted into the peripheral
region to avoid overdosing the urethra. In the operating room, patients are placed with their
legs in an elevated position, a Foley catheter is inserted, and a template is positioned against the
perineum. Ultrasound is the imaging modality utilised for the procedure to allow for the accurate
insertion of the brachytherapy needles into the Planned Target Volume (PTV) with the aid of a
template. Real-time treatment planning guides the radiation oncologist on where is best to locate
the seeds in terms of proximity to organs at risk (OARs) [1]. These seeds are usually Iodine-125,
with apparent activities of the individual seeds typically ranging from 0.357mCi to 0.42mCi, and
have a half-life of 59.43 days. They measure approximately 4.5 × 0.8mm, and generally 60 to
100 seeds may be placed, depending on the size of the prostate.
The International Commission on Radiological Protection (ICRP) Report Nos. 86 [2] and 97
[3] as well as International Atomic Energy Agency (IAEA) safety report series 17 [4] describe
errors that have occurred in brachytherapy as well as databases, such as ROSIS [5], SAFRON [6]
and ACCIRAD [7]. As demonstrated through phantom and computer-simulated error scenarios
[8–10], several of the reported BT error types could have been detected with real-time in-vivo
dosimetry. Human errors contribute to the majority of mistakes and accidents reported from
brachytherapy, although a few are related to technical issues [8]. This can be typically incorrect
patient demographics, seed radiation activity, prescribed total dose or simple software issues [8].
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Incorrect insertion of the seeds may also occur as it is a manual process and there is also the
probability of seed migration post procedure [8].
Uncertainties in the detector position may generate substantial dose uncertainties. It has been
reported that positional uncertainties <1.5mm for the dosimeter are required in order to be able to
detect source displacement errors of 5mm [9,10]. Poor image quality from ultrasound, alongside
patient organ movement throughout the procedure, can result in it being very difficult to maintain
a positional accuracy of <1.5mm [10]. An important factor in identifying potential errors
with in-vivo dosimetry (IVD) is the ability to place the sensor in a good location alongside the
capability to capture this position [8]. Present Treatment Planning Systems (TPS) incorporate the
American Association of Physicists in Medicine Task Group (TG)-43 dose calculation protocol
[11]. This does not take into account tissue heterogeneities by assuming the patient is made
of water. TPS rely on the correct inputted information detail, such as seed radiation activity
and the appropriate dose calculation protocol to be used. Variation of the delineation of PTV
and OARs are also created by different users of the system leading to further uncertainties
[12]. Shortcomings of the TG-43 dose calculation protocol [11] are targeted by developments
of model-based dose calculation methods, which in contrast to the TG-43, account for tissue
heterogeneities and individualized patient anatomy [13].
The inherent properties of optical fibers, e.g. lightweight, small dimensions, in addition to the
water equivalence of PMMA, make them suitable for in vivo radiotherapy applications [14]. This
paper presents a radiotherapy dosimeter based on optical fiber sensor technology, offering the
unique ability to directly measure the radiation dose administered to the tumour and surrounding
tissues. The measured radiation dose can be used to verify the calculated dose distribution that
describes the treatment received by the patient. Live measurements during the brachytherapy
procedure can allow optimisation during the procedure and result in high quality treatments.
The quality of a brachytherapy treatment is directly linked to patient survival and quality of
life [15]. Previous work by the authors has demonstrated the applicability of radioluminesence
for external beam radiotherapy monitoring, whereby plastic optical fibers are coated with the
scintillator [16]. This paper presents recent advancements in the development of an optical
fiber radioluminescence sensor developed by Woulfe et al. [17,18], whereby the radiation
sensitive scintillator, terbium-doped gadolinium oxysulphide (Gd2O2S:Tb), is embedded within
the core of a 1mm PMMA (Polymethyl methacrylate) plastic optical fiber. The sensor is further
characterised for a range of parameters, including angular dependence and distance from the
source. The results are further evaluated against theoretical dose calculations performed using
TG-43 formulism to independently verify the treatment planning system dose projections. This
work has expanded on the verification methods used to validate the sensor and its potential
clinical application in brachytherapy.
2. Sensor fabrication
The optical fiber sensor, shown in Fig. 1, is constructed by micromachining a cavity in the
1mm core of a PMMA (polymethyl methacrylate) plastic optical fiber [17]. The cavity, 700µm
in diameter and 7mm deep, is filled with a scintillating material, terbium doped gadolinium
oxysulphide (Gd2O2S:Tb, GOS) by inserting phosphor into an assembly, as shown in Fig. 2, and
sealed with an epoxy. This scintillation material was chosen based on the previously reported
work [19] that demonstrates the high light yield of Gd2O2S:Tb to the brachytherapy seeds. The
Gd2O2S:Tb type UKL65/F-R1, supplied by Phosphor Technology Ltd, UK has a green emission
colour with a median particle size of 3.5µm. On exposure to ionising radiation, it fluoresces at
the primary peak wavelength of 545 nm, with two smaller peaks observed at 490 nm and 590 nm.
The resultant emitted fluorescent light penetrates the PMMA optical fiber core and propagates
along the fiber to a Hamamatsu Multi-Pixel Photon Counting Module (MPPC) C13366 [20] for
monitoring of the optical signal.
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Fig. 1. Optical fiber based radiation dosimeter.
Fig. 2. Assembly to insert scintillating phosphor.
The small dimensions of the sensor, with an overall outer diameter of less than 1mm, mean that
they can be guided within existing brachytherapy equipment, for example within the brachytherapy
needle, as shown in Fig. 3. This will allow the sensor to be located directly within the prostate,
using techniques the radiation oncologist is already familiar with. The optical fiber sensor can
also be inserted through the transrectal biopsy guide of the ultrasound probe enabling dosimetry
feedback of dose to the surface of the rectal wall. This will provide real-time information of the
radiation dose received by the tumour and to the surrounding organs at risk (OARs).
Fig. 3. Optical fiber sensor within brachytherapy needle for direct tumour dose monitoring.
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3. Results and discussion
The optical fiber sensor was fixed within a novel prostate phantom, developed in-house using water
equivalent RW3 material (polystyrene with titanium oxide admixture), to allow for comparison
of results with the TG-43 Dose Calculation [21]. The TG-43 protocol has resulted in significant
improvements in the standardisation of both dose-calculation methodologies as well as dose rate
distributions used for clinical implementation of brachytherapy. The general, two-dimensional
(2D) dose-rate equation (Eq. (1)) from the 1995 TG-43 [21] protocol is retained,
D(r) = Sk · Λ ·
GL(r, θ0)
GL(r0, θ0)
· gL(r) · φan(r) (1)
where r denotes the distance (cm) from the centre of the active source to the point of interest, r0
denotes the reference distance which is specified to be 1 cm in this protocol, and θ denotes the
polar angle specifying the point of interest, P(r, θ), relative to the source longitudinal axis. Sk
defines Air Kerma Strength, Λ is the dose rate constant in water, G is Geometry function, gL(r) is
the radial dose function while φan(r) is 1D Anisotropy function. The reference angle, θ0, defines
the source transverse plane [22], specified to be 90° as per Fig. 4 [23]. L is defined as the active
length of the source and t is the thickness of outer capsule surrounding source.
Fig. 4. Coordinate system used for brachytherapy dosimetry calculations [23].
The experimental set-up can be seen in Fig. 5. The brachytherapy seeds were inserted into the
prostate phantom for a fixed period of time and the response of the sensor monitored. The sensor
was initially tested for its response to 0.361mCi of Iodine-125, for a comparison of optical signal.
Fig. 5. Optical fiber sensor within brachytherapy needle and located within the novel
prostate phantom.
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3.1. Repeatability
A single Iodine-125 seed, with a total activity of 0.361mCi, is inserted into the prostate phantom
and removed over three consecutive cycles to determine the stability and repeatability of the
sensor’s response. Due to health and safety in handling the radioactive seeds, the test was limited
to three iterations. Figure 6 shows the fluorescent signal for each of the three iterations. As the
brachytherapy seeds are inserted into the prostate phantom, there is a clear increase in photon
counts. A seed is inserted for a set period of time and then removed, as highlighted over three
iterations. The first measurement results show an average photon count of 4920, the second
5299 and finally the third 5107. The average photon count for all 3 repeated measurements was
5130. The position of the seed at coordinates x: 0.56 cm, y: 12.14 cm and z: 9.6 cm which is
5mm to the right of sensor equate to a dose of 34.67Gy, according to Eq. (1). For the remainder
of the paper, this point was used as the reference point for all measurements. The resultant
percentage variation from the mean was -4.1%, 3.3% and -0.45% for the three measurement
cycles respectively with a signal variation ranging from 0.56% to 2.4% of the signal. The
maximum percentage variation of 4.1% is within current acceptable standards for brachytherapy
dosimetry, although it is acknowledged that a more in depth analysis is required with additional
measurement sets.
Fig. 6. Repeatability of 0.361mCi Seed with Gd2O2S:Tb Dosimeter.
3.2. Angular dependency
The angular dependency of the dosimeter was investigated by monitoring the variation in the
optical signal at different angles to the dosimeter. Four angles were evaluated; 0, 90, 180 and 270
degrees, each located 0.5 cm from the centre position where the sensor was positioned. These
are depicted as 0.5 cm Top (1 T), 0.5 cm Right (1R), 0.5 cm Bottom (1B) and 0.5 cm Left (1L).
Figure 7 shows the noticeable difference in the response of the GOS at different angles. In terms
of photon counts, there is slight decrease of -1.6% for 1R and -5.5% for 1L, and an increase of
5.3% for 1 T and 6% for 1B. From above, we can also note the repeatability variation of 4.1%,
which potentially equates to a maximum error of 1.9% for angular dependency. This error may
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be due to the filling process of the phosphor and the determination of the correct volume of
phosphor uniformly distributed within the cavity. High intensity imaging may help to verify this
process.
Fig. 7. Various positions of 0.361mCi seed with Gd2O2S:Tb Dosimeter.
3.3. Distance
The response of the dosimeter with respect to the distance from the radiation seed was also
investigated. This was monitored in 0.5 cm steps up to 3 cm distance from the seed, whereby the
sensor was placed in the centre of the phantom and the radiation seed was moved in 0.5 cm steps
linearly away from the centre. Figure 8 shows that the sensor is capable of detecting activity up to
a distance of 3 cm for an activity of 0.361mCi. 3 cm is the distance required to achieve adequate
dosimetry coverage of an average sized prostate gland by having the sensor positioned within
the centre of the prostate gland. As can be seen, the response at 0.5 cm is 5498 photon counts
decreasing down to 154 photon counts for 3 cm, which is just above background. Any further
distance will not be detected adequately. Figure 8(b) shows the sensor’s response aligns well
with the theory in demonstrating the radiation’s dependence on the inverse-square law. Further
investigation will be performed in an anthropomorphic prostate simulation phantom.
3.4. Accumulated radiation activity
To monitor the sensor’s response to accumulated radiation activity, the sensor is placed in the
centre grid position; eight seeds are then inserted in various positions around the sensor. The
radio-active sources remain in the prostate phantom at a particular grid position at a depth of
4 cm, as each additional seed is added to the next grid position. The associated measured photon
count for a single seed equates to 152 for 1Gy of I-125. The expected point dose as each seed
is added to the respective grid positions is calculated from TG43. This is also used within the
Treatment Planning System Variseed (Fig. 9). Figure 10 shows the increase in the sensor’s optical
signal as each seed is introduced to the phantom.
The apparent activity of brachytherapy seeds, directly relate to the radiation dose the cancer
patient will receive during treatment. As the radiation activity increases, there is a discrete and
measurable difference in the response of the sensor to the different activity levels of the iodine
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Fig. 8. (a) Sensor response at different distances from the radiation source (b) Photon counts
as a function of the distance from the source, demonstrating the inverse-square relationship.
Research Article Vol. 11, No. 7 / 1 July 2020 / Biomedical Optics Express 4034
Fig. 9. Treatment Planning System (TPS) indicating Point Dose Expected TPS Values (Gy).
Fig. 10. Response of the Optical Fiber Sensor to I-125 seeds ranging from 0.361mCi up to
2.888mCi.
seeds with an increase in photon counts as shown in Fig. 10. The results demonstrate the sensor’s
capability of monitoring the placement of individual radiation seeds during LDR brachytherapy,
in addition to determining the overall radiation dose. A comparison between the measured dose
from the optical fiber sensor and the calculated TPS values is shown in Fig. 11. The dosimeter is
in excellent agreement with the expected dose with a maximum error of 4.13% at a seed activity
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of 0.361mCi. There is also a good linear response from the dosimeter to the expected dose, with
a linear regression of 0.9994.
Fig. 11. Comparison of Dosimeter to TG 43.
4. Discussion and conclusion
An optical fiber sensor, based on radioluminescence, is presented for monitoring the radiation dose
a cancer patient receives during seed implantation in brachytherapy. A cavity, 700µm in diameter
and 7mm deep, is micro-machined in the 1mm core of a PMMA plastic optical fiber and is filled
with a radiation sensitive scintillation material. Future work will be focusing on optimisation of
the output signal based on the cavity’s dimension and shape. The sensor demonstrates a clear and
measurable increase in photon counts when exposed to a single brachytherapy seed and exhibits a
linear relationship with increasing seeds. The sensor also demonstrates good repeatability, with a
maximum percentage error of 4.13% for 8 seeds when compared to the expected result from the
treatment planning system calculation algorithm, TG43. The sensor design is minimally invasive,
allowing the sensors to be placed within existing brachytherapy equipment. With the assistance
of live feedback of the radiation dose to the planned target volume (PTV) and the organs at risk
(OARs) from the sensors, the radiation oncologist is able to ensure accurate placement of the
radio-active sources. This will lead to the ultimate goal of improving patient outcomes.
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